-
1 week ago | 
parkinsonsnewstoday.com | Andrea Lobo |Lindsey Shapiro |Mary Chapman |Patricia Inacio
Treatment for up to three years with Onapgo (apomorphine hydrochloride) — approved in the U.S. earlier this year as an add-on therapy for advanced Parkinson’s disease — significantly and sustainably reduced off time, when symptoms are not fully controlled, in adults with the neurodegenerative condition. Importantly, the researchers noted, reductions in off periods were matched by improvements in good on time, when symptoms are well controlled, among patients taking part in a clinical study.
-
1 week ago | 
parkinsonsnewstoday.com | Lindsey Shapiro |Mary Chapman |Margarida Maia
A wearable sensor that’s designed to monitor and improve swallowing led to increased swallowing frequency for people with Parkinson’s disease in a small clinical study. The scientists believe the sensors are useful for continuous monitoring of swallowing dysfunction, or dysphagia, in Parkinson’s, and may be a way to help ease the symptom.
-
3 weeks ago | 
parkinsonsnewstoday.com | Andrea Lobo |Marisa Wexler |Mary Chapman |Catarina Silva
Researchers at the University of Delaware have developed a model that combines artificial intelligence with magnetic resonance elastography (MRE) to measure brain stiffness and volume for predicting brain age. MRE is a noninvasive method that can measure changes in brain stiffness by using a gentle vibration of a person’s head while they’re being scanned using MRI. This helps create a brain stiffness map based on how tissue in each part of it responds to a light touch.
-
1 month ago | 
parkinsonsnewstoday.com | Andrea Lobo |Mary Chapman |Lindsey Shapiro |Margarida Maia
Neuropacs‘ MRI-based artificial intelligence (AI) technology demonstrated 96% accuracy in distinguishing Parkinson’s disease from atypical parkinsonism — including multiple system atrophy, known as MSA, and progressive supranuclear palsy, called PSP — the company announced, detailing the results of a federally funded U.S. study.
-
1 month ago | 
parkinsonsnewstoday.com | Andrea Lobo |Margarida Maia |Marisa Wexler |Mary Chapman
Parkinson Italia — a network of 30 associations for patients and caregivers in Italy — is backing an initiative by the Prada Foundation that seeks to highlight the importance of prevention and early treatment of neurodegenerative diseases like Parkinson’s. The campaign, dubbed Preserving the Brain: A Call to Action, launched in the fall with a two-day scientific conference, “Prevention on Neurodegenerative Diseases,” in October.
-
1 month ago | 
parkinsonsnewstoday.com | Andrea Lobo |Margarida Maia |Mary Chapman |Lindsey Shapiro
The U.S. Food and Drug Administration (FDA) has listed MR-005, MedRhythms’ digital therapeutic platform using rhythmic beats to help with walking in Parkinson’s disease, as a Class II device requiring medical prescription. A Class II medical device is associated with a moderate to high risk to patients, and is subject to controls by the FDA that can include post-market surveillance. The company expects to launch MR-005, under the brand name Movive, in select U.S. markets in the coming months.
-
1 month ago | 
smanewstoday.com | Lindsey Shapiro |Katherine Poinsatte |Marta Costa Figueiredo |Mary Chapman
Tests by MRC Holland for identifying genetic mutations associated with spinal muscular atrophy (SMA) have met new regulatory requirements in the European Union (EU), enabling them to remain certified for diagnostic use. Products that have received the new certification include the MC002 Newborn Screen, MLPA Probemix P060 SMA Carrier, and MLPA Probemix P021 SMA.
-
1 month ago | 
parkinsonsnewstoday.com | Andrea Lobo |Marisa Wexler |Lindsey Shapiro |Mary Chapman
Onward Medical has received two grants totaling about $2.5 million to support early feasibility studies assessing whether its implantable spinal stimulation system, called ARC-IM, can lessen mobility difficulties and blood pressure instability in people with Parkinson’s disease.
-
1 month ago | 
parkinsonsnewstoday.com | Andrea Lobo |Patricia Inacio |Mollie Lombardi |Mary Chapman
A research advocate diagnosed with Parkinson’s disease and a former nurse with Alzheimer’s disease were among recipients of volunteer awards from the Global Alzheimer’s Platform Foundation (GAP). GAP’s Citizen Scientist Awards acknowledge the contributions of volunteers in clinical trials for neurodegenerative diseases. Each year, GAP’s network of research sites, GAP-Net, nominates trial volunteers, who share their journeys to encourage others in their communities to get involved in research.
-
1 month ago | 
parkinsonsnewstoday.com | Andrea Lobo |Marisa Wexler |Mary Chapman |Margarida Maia
Six months of treatment with intranasal FGF-1, a naturally occurring molecule that promotes blood vessel growth, improved blood flow in a brain region profoundly affected by Parkinson’s disease, along with motor function, in the first patient to undergo both assessments.
